76
|
Natori K, Ishihara S, Nagase D, Mitsui Y, Sakai A, Kato M, Kuraishi Y, Arai K, Izumi H. P-126 The cases that were diagnosed malignant lymphoma from gastrointestinal tract of biopsy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
77
|
Natori K, Nagase D, Ishihara S, Mitsui Y, Sakai A, Kato M, Kuraishi Y, Arai K, Izumi H. P-125 Study of multiple neoplasms consist of hematological malignancies and gastrointestinal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
78
|
Natori K, Ishihara S, Nagase D, Mitsui Y, Sakai A, Kuraishi Y, Kato M, Arai K, Izumi H. P-251 Diagnosis of malignant lymphoma during at the colorectal cancer surgery. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
79
|
Shibata J, Ishihara S, Tada N, Kawai K, Tsuno NH, Yamaguchi H, Sunami E, Kitayama J, Watanabe T. Surgical stress response after colorectal resection: a comparison of robotic, laparoscopic, and open surgery. Tech Coloproctol 2015; 19:275-80. [PMID: 25762242 DOI: 10.1007/s10151-014-1263-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2014] [Accepted: 12/20/2014] [Indexed: 12/14/2022]
Abstract
BACKGROUND The perioperative immune status of colorectal robotic surgery (RS), laparoscopic surgery (LS), and open surgery (OS) patients has not been compared. Our aim was to evaluate perioperative stress and immune response after RS, LS and OS. METHODS This prospective study included 46 colorectal surgery patients from the Department of Surgical Oncology of the University of Tokyo Hospital. Peripheral venous blood samples were obtained preoperatively and on postoperative days 1, 3, and 6. We evaluated expression of HLA-DR (marker of immune competence), C-reactive protein (CRP) levels, and lymphocyte subset counts (natural killers, cytotoxic T cells and helper T cells). RESULTS Fifteen, 23, and 8 patients underwent RS, LS and OS, respectively. HLA-DR expression was the lowest on day 1 and gradually increased on days 3 and 6 in all the groups. There was no significant difference in postoperative HLA-DR expression between the RS and LS group. However, on day 3, HLA-DR expression in the RS group was significantly higher than in the OS group (p = 0.04). On day 1, CRP levels in the LS group were significantly lower than in the RS group (p = 0.038). There were no significant perioperative changes in the lymphocyte subset cell count between the three groups. CONCLUSIONS Perioperative surgical stress, as evaluated by immunological parameters, was comparable between robotic and laparoscopic surgery and higher with open surgery. Robotic surgery may be an alternative to laparoscopic surgery, as a minimally invasive surgery option for colorectal cancer.
Collapse
|
80
|
Kikuta S, Miki R, Ishihara S, Nakayama S. Protective effect of a fecal incontinence management system against bacteremia for out-of-hospital cardiac arrest patients undergoing extracorporeal membrane oxygenation. Crit Care 2015. [PMCID: PMC4472675 DOI: 10.1186/cc14182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
81
|
Ishihara S, Kashiwagi S, Asano Y, Morisaki T, Noda S, Kawajiri H, Takashima T, Onoda N, Ohsawa M, Hirakawa K. [Four cases of malignant primary breast lymphoma]. Gan To Kagaku Ryoho 2014; 41:1942-1944. [PMID: 25731383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Primary malignant lymphoma of the breast (PBL) is comparatively rare in Japan.Herein, the authors present report 4 cases of PBL. All patients had the primary finding of a palpable left breast mass.Malignant lymphoma was strongly suspected by core needle biopsy, and final diagnosis was made on surgical specimens. All cases were diffuse large B-cell lymphoma and were treated with targeted chemotherapy with R-CHOP. Only 1 of the 4 patients needed multidisciplinary therapy due to advanced age.Whenever PBL is suspected, targeted therapy should be considered.
Collapse
|
82
|
Tokumoto M, Kashiwagi S, Ishihara S, Asano Y, Sakimura C, Kurata K, Tauchi Y, Morisaki T, Noda S, Kawajiri H, Takashima T, Onoda N, Hirakawa K. [Clinical experience with a handheld vacuum-assisted biopsy system (VACORA® )for mammary lesions]. Gan To Kagaku Ryoho 2014; 41:1887-1889. [PMID: 25731364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We evaluated the usefulness and safety of a handheld vacuum-assisted biopsy system (VACORA®) in 253 lesions suspected to be malignant. Biopsy samples were successfully obtained from 252 lesions, and no complications occurred that required other treatments during or after the biopsy. The definitive diagnosis rate using VACORA / ®was 89.3% (226/253). For 27 lesions, biopsy using Mammotome®or open biopsy was performed because a diagnosis could not be made with the VACORA® system, despite a category 4 result on ultrasonography. The lesions that were diagnosed as benign using the VACORA® system did not manifest malignant features during the observation period (1-36 months). We considered the VACORA® biopsy system as an effective technique that has both convenience and high diagnostic accuracy.
Collapse
|
83
|
Tanaka R, Kashiwagi S, Ishihara S, Asano Y, Noda S, Kawajiri H, Takashima T, Onoda N, Ohsawa M, Hirakawa K. [A case of malignant melanoma metastasis to the mammary gland]. Gan To Kagaku Ryoho 2014; 41:1939-1941. [PMID: 25731382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Herein, we report a rare case of malignant melanoma metastasis to the mammary gland. A 76-year-old woman had a tumor resection performed for primary malignant melanoma of the epipharynx. The patient subsequently underwent local and lymph node recurrence, for which she received heavy ion radiotherapy and lymph node dissection, respectively. The patient was referred to our hospital for a problem with her right breast. Computed tomography and magnetic resonance imaging showed a mammary tumor and multiple subcutaneous tumors. A biopsy was performed, which proved positive for S100 and Melan A staining, and the diagnosis of malignant melanoma was confirmed. Partial mastectomy was performed; and S100, HMB45, and Melan A positivity was confirmed based on immunohistological findings. The diagnosis was malignant melanoma metastasis to the mammary gland. Malignant melanoma commonly metastasizes to the liver, mediastinum, mediastinal glands, lung, and brain; and metastasis to the mammary gland is rare. To our knowledge, only 2 cases have previously been reported in the Japanese literature.
Collapse
|
84
|
Kashiwagi S, Ishihara S, Asano Y, Kurata K, Tauchi Y, Tokumoto M, Morisaki T, Noda S, Kawajiri H, Takashima T, Onoda N, Hirakawa K. [Eribulin chemotherapy after taxane treatment in advanced metastatic breast cancer]. Gan To Kagaku Ryoho 2014; 41:1951-1953. [PMID: 25731386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Clinical outcomes, including adverse events, in 52 advanced breast cancer patients treated with eribulin chemotherapy after taxane treatment (TX) were analyzed to confirm the effectiveness and safety of this treatment.The objective response rate (ORR) in patients was 34.6% (TX group 31.6%, non-TX group 36.4%). There were no significant differences in overall survival, time to treatment failure, or progression-free between three TX and non-TX groups. Further, adverse events did not differ between groups expression of neutropenia of Grade 3 or more. On the other hand, the number of patients with sensory peripheral neuropathy of Grade 1 or more was significantly more in the TX group than in the non-TX group. Eribulin chemotherapy was effective for the treatment of advanced breast cancer regardless of a history of taxane treatment.In addition, sensory peripheral neuropathy is a possible complication that can occur in advanced breast cancer patients treated with eribulin chemotherapy with taxane treatment history.
Collapse
|
85
|
Tauchi Y, Kashiwagi S, Ishihara S, Asano Y, Sakimura C, Kurata K, Tokumoto M, Morisaki T, Noda S, Kawajiri H, Takashima T, Onoda N, Hirakawa K. [Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer]. Gan To Kagaku Ryoho 2014; 41:1948-1950. [PMID: 25731385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Nanoparticle albumin-bound paclitaxel (nab-PTX, Abraxane®) does not require premedication, and it can be used for patients with alcohol intolerance. We administered nab-PTX to 31 patients with breast cancer between October 2010 and April 2013. Eighteen patients had progressive, recurring breast cancers and 13 patients had locally advanced operable breast cancers. The treatment schedules were 175 or 260 mg/m² every 3 weeks (q3w). No patient experienced an allergic reaction. Grade 1-3 sensory neuropathies were observed in 20 patients; however, no patient experienced grade 4 neuropathy. In patients with locally advanced, operable breast cancer, 1 patient treated with 175 mg/m² q3w had a partial response (PR), while of the patients treated with 260 mg/m² q3w, 10 patients showed a PR, and 1 patient had stable disease (SD). Of the patients with progressive, recurring breast cancer, 2 patients showed a PR and 4 patients had SD when treated with 175 mg/m² q3w, whereas 1 patient displayed a PR and 1 patient had SD when treated with 260 mg/m² q3w. Our investigation suggests that nab-PTX is well tolerated, even by patients with advanced breast cancer.
Collapse
|
86
|
Maebayashi T, Ishikawa H, Yorozu A, Yoshida D, Katoh H, Nemoto K, Ishihara S, Takemoto S, Ishibashi N, Tokumaru S, Akimoto T. Patterns of Practice in the Radiation Therapy for Bladder Cancer: Survey of the Japanese Radiation Oncology Study Group (JROSG). Jpn J Clin Oncol 2014; 44:1109-15. [DOI: 10.1093/jjco/hyu129] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
87
|
Minezaki H, Ishihara S, Uchida T, Muramatsu M, Rácz R, Asaji T, Kitagawa A, Kato Y, Biri S, Yoshida Y. Synthesis of endohedral iron-fullerenes by ion implantation. THE REVIEW OF SCIENTIFIC INSTRUMENTS 2014; 85:02A945. [PMID: 24593524 DOI: 10.1063/1.4850756] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In this paper, we discuss the results of our study of the synthesis of endohedral iron-fullerenes. A low energy Fe(+) ion beam was irradiated to C60 thin film by using a deceleration system. Fe(+)-irradiated C60 thin film was analyzed by high performance liquid chromatography and laser desorption/ ionization time-of-flight mass spectrometry. We investigated the performance of the deceleration system for using a Fe(+) beam with low energy. In addition, we attempted to isolate the synthesized material from a Fe(+)-irradiated C60 thin film by high performance liquid chromatography.
Collapse
|
88
|
Uchida T, Minezaki H, Ishihara S, Muramatsu M, Rácz R, Asaji T, Kitagawa A, Kato Y, Biri S, Drentje AG, Yoshida Y. Status of the Bio-Nano electron cyclotron resonance ion source at Toyo University. THE REVIEW OF SCIENTIFIC INSTRUMENTS 2014; 85:02C317. [PMID: 24593654 DOI: 10.1063/1.4862212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In the paper, the material science experiments, carried out recently using the Bio-Nano electron cyclotron resonance ion source (ECRIS) at Toyo University, are reported. We have investigated several methods to synthesize endohedral C60 using ion-ion and ion-molecule collision reaction in the ECRIS. Because of the simplicity of the configuration, we can install a large choice of additional equipment in the ECRIS. The Bio-Nano ECRIS is suitable not only to test the materials production but also to test technical developments to improve or understand the performance of an ECRIS.
Collapse
|
89
|
Asaji T, Ohba T, Uchida T, Minezaki H, Ishihara S, Racz R, Muramatsu M, Biri S, Kitagawa A, Kato Y, Yoshida Y. Fullerene-rare gas mixed plasmas in an electron cyclotron resonance ion source. THE REVIEW OF SCIENTIFIC INSTRUMENTS 2014; 85:02A936. [PMID: 24593515 DOI: 10.1063/1.4847255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A synthesis technology of endohedral fullerenes such as Fe@C60 has developed with an electron cyclotron resonance (ECR) ion source. The production of N@C60 was reported. However, the yield was quite low, since most fullerene molecules were broken in the ECR plasma. We have adopted gas-mixing techniques in order to cool the plasma and then reduce fullerene dissociation. Mass spectra of ion beams extracted from fullerene-He, Ar or Xe mixed plasmas were observed with a Faraday cup. From the results, the He gas mixing technique is effective against fullerene destruction.
Collapse
|
90
|
Nogami T, Taira N, Mizoo T, Nishiyama K, Iwamoto T, Motoki T, Shien T, Matsuoka J, Doihara H, Ishihara S, Kawai H, Kawasaki K, Ogasawara Y, Ishibe Y. Abstract P2-01-07: Analysis of the relationship between breast cancer risk-related gene polymorphisms, ESR1/6q25.1-rs2046210 and mammographic breast density. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-01-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Based on the results of a case-control study performed in Japan (Okayama and Kagawa), it was revealed that gene polymorphisms of the estrogen receptor (single nucleotide polymorphisms, SNPs), ESR1/6q25.1-rs2046210 and rs3757318, were closely related to breast cancer risk in Japanese women, and that the odds ratios per allele of individual SNPs were 1.37 [95% CI: 1.1 - 1.7] and 1.33 [1.04 - 1.7], respectively (San Antonio Breast Cancer Symposium 2012, Mizoo et al.). To examine the effects of these SNPs on the pathogenic mechanism of breast cancer, we analyzed the relationship of SNPs with reproductive/physiological factors (age of menarche and number of births), physical factors (height and Body Mass Index [BMI]), family history and mammographic breast density.
Methods: Among the patients enrolled in the case-control study, the patients who could be evaluated regarding their lifestyle, SNPs and mammographic breast density were divided into the case group (N = 394) and the control group (N = 511) as the dataset for the study. SNPs were analyzed using the TaqMan genotyping assay® for blood samples. In the analysis of the relationship between SNPs and breast cancer risk, the odds ratios (OR) and 95% confidence intervals (95%CI) were calculated using logistic regression analysis. For the analysis of the relationship between SNPs and the factors, t-test and chi-square test were used.
Results: In our dataset, the age-adjusted OR [95% CI] of ESR1/6q25.1-rs2046210 and rs3757318 were 2.22 [1.41 - 3.55] (AA vs. GG) and 2.12 [1.2 - 3.8] (AA vs. GG), respectively, suggesting that they would be significant risk factors. As a result of analyzing the relationship between SNPs and other factors, a significantly lower BMI was observed for the risk allele AA/AG of rs2046210, compared to GG (p = 0.014, t-test). Regarding the mammographic breast density, a significantly higher proportion of mammary glands with high density was confirmed for the risk allele AA/AG of rs2046210, compared to GG (p = 0.0389, chi-square test). The tendency towards a high mammographic breast density in the rs2046210 risk allele AA/AG was also confirmed based upon a stratified analysis of the case and control groups before and after menopause, and a significant correlation was observed, especially before menopause (p = 0.026, chi-square test).
Conclusion: Mammographic high breast density is generally considered as one of the breast cancer risks, and it was suggested that gene polymorphisms of ESR1/6q25.1-rs2046210 might affect mammographic breast density.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-01-07.
Collapse
|
91
|
Taira N, Mizoo T, Nishiyama K, Nogami T, Iwamoto T, Motoki T, Shien T, Matsuoka J, Doihara H, Ishihara S, Kawai H, Kawasaki K, Ogasawara Y, Ishibe Y. Abstract P3-07-10: Breast cancer risk-related gene polymorphisms, ESR1/6q25.1-rs2046210 and rs3757318, and clinical characteristics of breast cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-07-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background] Based on the results of a case-control study performed in Japan (Okayama and Kagawa), it was revealed that gene polymorphisms of the estrogen receptor (single nucleotide polymorphisms, SNPs), ESR1/6q25.1-rs2046210 and SNPs of rs3757318 were closely related to breast cancer risk in Japanese women, and that the odds ratio per allele of individual SNPs were 1.37 [95% CI: 1.1 - 1.7] and 1.33 [1.04 - 1.7], respectively (San Antonio Breast Cancer Symposium 2012, Mizoo et al.). We analyzed the relationship of ESR1/6q25.1-rs2046210 and rs3757318 SNPs with the clinical characteristics of breast cancer patients.
[Methods] Among the patients enrolled in the case-control study, 508 breast cancer patients who underwent genotyping for ESR1/6q25.1-rs2046210 and rs3757318 were analyzed as the subjects. SNPs were analyzed using the TaqMan genotyping assay® for blood samples. To analyze the relationship of genotypes (AA/GG, GG) with age at diagnosis, height, weight, BMI, age of menarche, birth history, pathological degree of progression and estrogen receptor, t-test and chi-square test were used.
[Results] The genotypes of rs2046210 are AA (12%), AG (41%) and GG (46%), and the patients with the risk allele (AA/AG) had significantly higher height (p = 0.0015, t-test) and lower Body Mass Index (BMI) (p = 0.0022, t-test). The genotypes of rs3757318 are AA (8%), AG (39%) and GG (53%), and the patients with the risk allele (AA/AG) were characterized by significantly lower BMI (p = 0.041, t-test), no birth history (p = 0.0473, chi-square) and negative hormone receptor (p = 0.0128, chi-square). Overall, tendencies related to increased height, lower BMI and negative estrogen receptor were confirmed for the risk alleles of rs2046210 and rs3757318.
[Conclusion] It was suggested that SNPs of rs2046210 and rs3757318 might be related to the development of estrogen-receptor-negative breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-07-10.
Collapse
|
92
|
Aomatsu N, Kashiwagi S, Morisaki T, Ishihara S, Asano Y, Watanabe M, Noda S, Kawajiri H, Takashima T, Onoda N, Ishikawa T, Hirakawa K. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer]. Gan To Kagaku Ryoho 2013; 40:2393-2395. [PMID: 24394123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Bevacizumab combination chemotherapy prolongs progression-free survival but not overall survival in patients with advanced breast cancer. Here, we report our experience with bevacizumab plus paclitaxel treatment in our department. We believe that this regimen confers some benefit to a patient's quality of life. Nineteen patients with inoperable, metastatic, or recurrent breast cancer were treated with bevacizumab plus paclitaxel. The median age was 55 years; all patients were females. Of the 19 patients, 14, 1, and 4 had luminal A, luminal B, and triple-negative type tumors, respectively. The response rate was 63%: partial response (PR) was obtained in 12 patients, stable disease (SD) in 5 patients, and progressive disease( PD) in 2 patients. Adverse events of Grade 3 or more were high blood pressure( 4 patients), peripheral neuropathy (1 patient), and neutropenia (9 patients). All side effects could be tolerated. There was a high rate of response to bevacizumab plus paclitaxel chemotherapy. We believe that this chemotherapy is useful in patients with more advanced breast cancer in whom a high response rate is required.
Collapse
|
93
|
Kashiwagi S, Ishihara S, Ishii M, Asano Y, Watanabe M, Morisaki T, Aomatsu N, Noda S, Kawajiri H, Nakano T, Kawakami N, Mitsukawa Y, Takashima T, Onoda N, Ishikawa T, Hirakawa K. [Our experience of eribulin treatment in advanced breast cancer]. Gan To Kagaku Ryoho 2013; 40:1581-1583. [PMID: 24393855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The clinical outcomes, including adverse events, in 40 advanced breast cancer patients treated with eribulin were analyzed to confirm the effectiveness and safety of this treatment. The objective response rate (ORR) in patients was 35.0%. The median overall survival and time to treatment failure (TTF) in these patients was 479 and 63 days, respectively. Cases wherein eribulin was used as early-line treatment experienced significantly longer TTF compared to the cases wherein eribulin was used as late-line treatment; however, there was no difference in this value according to the breast cancer subtype. Moreover, subtype analysis revealed no significant difference in adverse events. We observed no difference in the benefit or tolerability of eribulin treatment among different breast cancer subtypes. However, our results suggest that a significant therapeutic effect can be expected when using eribulin as early-line treatment.
Collapse
|
94
|
Kashiwagi S, Ishihara S, Ishii M, Asano Y, Watanabe M, Morisaki T, Aomatsu N, Noda S, Kawajiri H, Nakano T, Kawakami N, Mitsukawa Y, Takashima T, Onoda N, Ishikawa T, Hirakawa K. [Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery]. Gan To Kagaku Ryoho 2013; 40:2384-2386. [PMID: 24394120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A 58-year-old woman observed swelling in her left breast a few weeks prior to presentation. Rigidity in the D area, breast warmth, swelling, and a peau d'orange appearance in the whole left breast was observed. She was diagnosed with inflammatory breast cancer (luminal A type) T4dN2M0, Stage IIIB. The patient underwent primary systemic therapy with 7 courses of FEC. Following FEC treatment, the disease was stable. We subsequently administered 4 courses of bevacizumab plus paclitaxel combination therapy. The patient exhibited a partial response to FEC chemotherapy. Thereafter, a left mastectomy with level II axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer.
Collapse
|
95
|
Kashiwagi S, Okuno T, Ishihara S, Ishii M, Asano Y, Watanabe M, Morisaki T, Aomatsu N, Noda S, Kawajiri H, Nakano T, Kawakami N, Mitsukawa Y, Takashima T, Onoda N, Ishikawa T, Hirakawa K. [Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast]. Gan To Kagaku Ryoho 2013; 40:2369-2371. [PMID: 24394115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The patient was a 40-year-old woman who was aware of a tumor in her left breast that was gradually increasing in size. Ultrasonography revealed a hypoechoic mass with a skin cyst, approximately 3 cm in size, in the C area of the left breast. Core needle biopsy indicated estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and human epidermal growth factor receptor 2 (HER2) -negative squamous cell carcinoma. Overall examination did not indicate distant metastasis. A diagnosis of T4bN2aM0, stage IIIB triple-negative left breast cancer was made. Eribulin was administered at a dose of 1.4 mg/m2. The effect of eribulin was considered to be long-term stable disease( long-term SD). The patient did not experience severe adverse events during treatment. After 24 weeks of eribulin treatment, mastectomy of the left breast with axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that eribulin chemotherapy is useful for the treatment of patients with squamous cell carcinoma of the breast.
Collapse
|
96
|
Ishihara S, Watanabe T, Fukushima Y, Akahane T, Horiuchi A, Shimada R, Nakamura K, Hayama T, Yamada H, Nozawa K, Matsuda K, Hashiguchi Y. Safety and factors contributing to the difficulty of laparoscopic surgery for rectal cancer treated with preoperative chemoradiotherapy. Tech Coloproctol 2013; 18:247-55. [DOI: 10.1007/s10151-013-1048-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2013] [Accepted: 07/02/2013] [Indexed: 01/17/2023]
|
97
|
Natori K, Nagase D, Ishihara S, Shibuya A, Toyoda Y, Kato M, Kuraishi Y, Izumi H. Therapy in malignant lymphoma in 80 years or over. Eur Geriatr Med 2013. [DOI: 10.1016/j.eurger.2013.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
98
|
Natori K, Nagase D, Ishihara S, Shibuya A, Toyoda Y, Kato M, Kuraishi Y, Izumi H. Multiple neoplasms including hematological malignancies in elderly. Eur Geriatr Med 2013. [DOI: 10.1016/j.eurger.2013.07.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
99
|
Natori K, Nagase D, Ishihara S, Shibuya A, Toyoda Y, Kato M, Kuraishi Y, Izumi H. Study of malignant lymphoma diagnosed by biopsy from head and neck area in elderly. Eur Geriatr Med 2013. [DOI: 10.1016/j.eurger.2013.07.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
100
|
Natori K, Nagase D, Ishihara S, Shibuya A, Toyoda Y, Kato M, Kuraishi Y, Izumi H. Leukemia in elderly. Eur Geriatr Med 2013. [DOI: 10.1016/j.eurger.2013.07.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|